Save hours of research with our analyst-prepared profile on Viatris. Get financials, SWOT, and competitor insights in one place—your competitors might already have it.
| Competitor | Headquarters | No. of Employees | Revenue | Entity Type |
|---|---|---|---|---|
Pfizer | United States of America | 79,000 | $51.75B | Public |
AbbVie | United States of America | 47,000 | $56.2B | Public |
Johnson & Johnson | United States of America | 132,200 | $94.9B | Public |
Novartis | Switzerland | 110,000 | $48.3B | Public |
Merck & Co. | United States of America | 74,000 | $48.2B | Public |
AstraZeneca | United Kingdom | 76,600 | $44.4B | Public |
Roche | Switzerland | 97,700 | $68B | Public |
GSK (GlaxoSmithKline) | United Kingdom | 99,000 | $46.8B | Public |
Sanofi | France | 100,000 | $43.9B | Public |
Bristol-Myers Squibb | United States of America | 30,000 | $46.1B | Public |
Amgen | United States of America | 23,000 | $26B | Public |
Eli Lilly | United States of America | 35,000 | $28.5B | Public |
Teva Pharmaceutical Industries | Israel | 38,000 | $18.7B | Public |
Sun Pharmaceutical Industries | India | 31,000 | $4.9B | Public |
Takeda Pharmaceutical Company | Japan | 50,000 | $30.8B | Public |
Viatris operates in a highly competitive pharmaceutical industry with several major players. The leading competitors include Pfizer, AbbVie, and Johnson & Johnson, each commanding significant market share and extensive research capabilities. Companies like Novartis and Merck & Co. bring strong innovation pipelines to the market. As the sector continues to evolve, traditional pharmaceutical giants such as GSK and Sanofi maintain robust portfolios across numerous therapeutic areas. This competitive landscape pushes Viatris to continuously innovate and seek strategic partnerships, emphasizing the importance of adaptability and resource efficiency in a diverse marketplace.
Viatris operates in a highly competitive pharmaceutical industry with several major players. The leading competitors include Pfizer, AbbVie, and Johnson & Johnson, each commanding significant market share and extensive research capabilities. Companies like Novartis and Merck & Co. bring strong innovation pipelines to the market. As the sector continues to evolve, traditional pharmaceutical giants such as GSK and Sanofi maintain robust portfolios across numerous therapeutic areas. This competitive landscape pushes Viatris to continuously innovate and seek strategic partnerships, emphasizing the importance of adaptability and resource efficiency in a diverse marketplace.
